COSCIENS Biopharma (TSE:CSCI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
COSCIENS Biopharma Inc., a biopharmaceutical company known for its diverse portfolio including the FDA-approved oral test for adult growth hormone deficiency, has announced the immediate resignation of Carolyn Egbert from its Board of Directors. The company expressed gratitude for Egbert’s contributions, particularly during her eight years as Chair, and revealed plans to restructure the Board to consist of six members. This move is aimed to align with industry standards for a company at COSCIENS’ stage of development.
For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.